Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bimekizumab 2mL vs 1mL SC Injection
NCT04255862Phase 1Terminated
- Sponsor
- UCB
- Start
- Feb 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bimekizumab in plaque psoriasis (4 arms), sponsored by UCB. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity, Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration and 1 more. Started Feb 2020; status: terminated.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04255862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255862.